Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.